当前位置：
X-MOL 学术
›
Adv. Drug Deliver. Rev.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Novel strategies for modulating the gut microbiome for cancer therapy
Advanced Drug Delivery Reviews ( IF 15.2 ) Pub Date : 2024-05-15 , DOI: 10.1016/j.addr.2024.115332 Young Seok Cho 1 , Kai Han 2 , Jin Xu 1 , James J Moon 3
Advanced Drug Delivery Reviews ( IF 15.2 ) Pub Date : 2024-05-15 , DOI: 10.1016/j.addr.2024.115332 Young Seok Cho 1 , Kai Han 2 , Jin Xu 1 , James J Moon 3
Affiliation
|
Recent advancements in genomics, transcriptomics, and metabolomics have significantly advanced our understanding of the human gut microbiome and its impact on the efficacy and toxicity of anti-cancer therapeutics, including chemotherapy, immunotherapy, and radiotherapy. In particular, prebiotics, probiotics, and postbiotics are recognized for their unique properties in modulating the gut microbiota, maintaining the intestinal barrier, and regulating immune cells, thus emerging as new cancer treatment modalities. However, clinical translation of microbiome-based therapy is still in its early stages, facing challenges to overcome physicochemical and biological barriers of the gastrointestinal tract, enhance target-specific delivery, and improve drug bioavailability. This review aims to highlight the impact of prebiotics, probiotics, and postbiotics on the gut microbiome and their efficacy as cancer treatment modalities. Additionally, we summarize recent innovative engineering strategies designed to overcome challenges associated with oral administration of anti-cancer treatments. Moreover, we will explore the potential benefits of engineered gut microbiome-modulating approaches in ameliorating the side effects of immunotherapy and chemotherapy.
中文翻译：
调节肠道微生物组以治疗癌症的新策略
基因组学、转录组学和代谢组学的最新进展极大地增进了我们对人类肠道微生物组及其对抗癌治疗（包括化疗、免疫治疗和放疗）疗效和毒性影响的理解。特别是，益生元、益生菌和后生元因其在调节肠道微生物群、维持肠道屏障和调节免疫细胞方面的独特特性而受到认可，从而成为新的癌症治疗方式。然而，基于微生物组的疗法的临床转化仍处于早期阶段，面临着克服胃肠道的理化和生物屏障、增强目标特异性递送和提高药物生物利用度的挑战。本综述旨在强调益生元、益生菌和后生元对肠道微生物组的影响及其作为癌症治疗方式的功效。此外，我们总结了最近旨在克服与口服抗癌治疗相关的挑战的创新工程策略。此外，我们将探索工程化肠道微生物组调节方法在改善免疫疗法和化疗副作用方面的潜在益处。
更新日期：2024-05-15
中文翻译：
调节肠道微生物组以治疗癌症的新策略
基因组学、转录组学和代谢组学的最新进展极大地增进了我们对人类肠道微生物组及其对抗癌治疗（包括化疗、免疫治疗和放疗）疗效和毒性影响的理解。特别是，益生元、益生菌和后生元因其在调节肠道微生物群、维持肠道屏障和调节免疫细胞方面的独特特性而受到认可，从而成为新的癌症治疗方式。然而，基于微生物组的疗法的临床转化仍处于早期阶段，面临着克服胃肠道的理化和生物屏障、增强目标特异性递送和提高药物生物利用度的挑战。本综述旨在强调益生元、益生菌和后生元对肠道微生物组的影响及其作为癌症治疗方式的功效。此外，我们总结了最近旨在克服与口服抗癌治疗相关的挑战的创新工程策略。此外，我们将探索工程化肠道微生物组调节方法在改善免疫疗法和化疗副作用方面的潜在益处。
京公网安备 11010802027423号